News & Events

ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

NASH Clearing Clinical Trial Hurdles in Race to $35 billion Market

Linked to the global obesity epidemic, non-alcoholic steatohepatitis (NASH) ranks among the world’s great emerging health threats. A silently progressing chronic condition that develops from non-alcoholic fatty liver disease, NASH affects up to 10 percent of the USA and European Union populations. It causes cirrhosis and liver cancer, and is projected to surpass hepatitis C and alcoholic cirrhosis as the leading indication for liver transplantation by 2020.

Discover more solutions and insights from our experts

Download the rest of this blog to discover more solutions and insights from our experts to address the growing unmet clinical need for NASH treatments.